Why Doctors Pay Nothing and Pharma Pays Per Visit

We get asked a version of the same question in almost every pharma sales conversation about Connex: why is the doctor side entirely free, and why does pharma only pay for visits that actually complete and verify?

The short answer is that any other model breaks the marketplace before it starts.

Why doctors cannot pay

Doctors are not our customer in the traditional sense, they are the supply side of a two-sided marketplace, and supply-side users in any marketplace adopt a product because it is genuinely free and useful, not because someone convinced them to invest in it. The moment a scheduling tool asks a doctor for money, or asks for enough time and setup that it feels like an obligation, adoption collapses. We have no interest in building a product doctors have to be talked into.

Why pharma pays per verified visit, not per seat

Pharma companies buy credits, and a credit is only spent when a visit actually completes and passes verification, whether that verification comes from GPS-and-QR confirmation for an in-person visit or captured consent for a virtual one.

• •A booked slot that a rep no-shows for costs nothing
• •A visit that fails GPS or QR verification is not charged, because it cannot be proven to have happened as claimed
• •A completed, verified visit is the only event that draws down a credit, which means pharma is paying for evidence, not for effort
• •This also removes any incentive for us to inflate booking numbers, since our revenue only grows when real, verifiable engagement grows

The alignment this creates

This structure lines up the incentives of all three parties in a way flat licensing fees never do. Doctors get a free tool with no strings attached. Pharma companies get a bill that maps directly to real, compliant field activity rather than a subscription they have to justify internally regardless of usage. And we only succeed if visits are genuinely happening and genuinely verifying, which keeps us honest about the quality of the verification itself.

We considered simpler pricing models before landing here, including flat per-seat licensing for pharma teams. Every one of them either put a cost on the doctor side or decoupled our revenue from actual verified outcomes. Per-visit credits was the only model that kept everyone's incentives pointed the same direction.